The perlecan fragment LG3 is a novel regulator of obliterative remodeling associated with allograft vascular rejection

Circulation Research

Volumn 110, Issue 1, 2012, Pages 94-104

  Soulez, Mathilde ^a   Pilon, Eve Annie ^a   Dieudé, Mélanie ^a   Cardinal, Héloïse ^a   Brassard, Nathalie ^a   Qi, Shijie ^a   Wu, Shyh Jong ^a   Durocher, Yves ^b   Madore, François ^c   Perreault, Claude ^d   Hébert, Marie Josée ^a  

^a NOTRE DAME HOSPITAL   (Canada)

^b NATIONAL RESEARCH COUNCIL CANADA   (Canada)

^c HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

^d INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

Author keywords

apoptosis; endothelial cell; extracellular matrix; kidney; neointima

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CD31 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PERLECAN; PERLECAN C TERMINAL FRAGMENT LG3; UNCLASSIFIED DRUG;

ACUTE VASCULAR REJECTION; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA GRAFT; ARTICLE; CELL MIGRATION; CONTROLLED STUDY; FEMALE; GRAFT FAILURE; GRAFT REJECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY ALLOGRAFT; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MOUSE; NEOINTIMA; NONHUMAN; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER; TUBULO INTERSTITIAL REJECTION;

ADULT; ANIMALS; AORTA; APOPTOSIS; CASE-CONTROL STUDIES; CELL MOVEMENT; CELLS, CULTURED; FEMALE; GRAFT REJECTION; HEPARAN SULFATE PROTEOGLYCANS; HUMANS; KIDNEY TRANSPLANTATION; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MIDDLE AGED; MODELS, ANIMAL; MUSCLE, SMOOTH, VASCULAR; NEOINTIMA; NEOVASCULARIZATION, PHYSIOLOGIC; PEPTIDE FRAGMENTS; PROGNOSIS; RATS; RETROSPECTIVE STUDIES; TRANSPLANTATION, HOMOLOGOUS;

EID: 84855393703     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.111.250431     Document Type: Article

References (30)

1. Cailhier JF, Laplante P, Hebert MJ. Endothelial apoptosis and chronic transplant vasculopathy: recent results, novel mechanisms. Am J Transplant. 2006;6:247-253. (Pubitemid 43382159)
2. Rahmani M, Cruz RP, Granville DJ, McManus BM. Allograft vasculopathy versus atherosclerosis. Circ Res. 2006;99:801-815. (Pubitemid 44556379)
3. Cornell LD, Smith RN, Colvin RB. Kidney transplantation: mechanisms of rejection and acceptance. Annu Rev Pathol. 2008;3:189-220. (Pubitemid 351488280)
4. Newby AC, Zaltsman AB. Molecular mechanisms in intimal hyperplasia. J Pathol. 2000;190:300-309. (Pubitemid 30141376)
5. K/doqi clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:S1-S266.
6. Xu Q. Stem cells and transplant arteriosclerosis. Circ Res. 2008;102: 1011-1024. (Pubitemid 351667855)
7. Boersema M, Rienstra H, van den Heuvel M, van Goor H, van Luyn MJ, Navis GJ, Popa ER, Hillebrands JL. Donor and recipient contribution to transplant vasculopathy in chronic renal transplant dysfunction. Transplantation. 2009;88:1386-1392.
8. Davis GE. Matricryptic sites control tissue injury responses in the cardiovascular system: relationships to pattern recognition receptor regulated events. J Mol Cell Cardiol. 2010;48:454-460.
9. Marneros AG, Olsen BR. The role of collagen-derived proteolytic fragments in angiogenesis. Matrix Biol. 2001;20:337-345. (Pubitemid 32846719)
10. Bix G, Castello R, Burrows M, Zoeller JJ, Weech M, Iozzo RA, Cardi C, Thakur ML, Barker CA, Camphausen K, Iozzo RV. Endorepellin in vivo: targeting the tumor vasculature and retarding cancer growth and metabolism. J Natl Cancer Inst. 2006;98:1634-1646. (Pubitemid 44811646)
11. Cailhier JF, Sirois I, Laplante P, Lepage S, Raymond MA, Brassard N, Prat A, Iozzo RV, Pshezhetsky AV, Hebert MJ. Caspase-3 activation triggers extracellular cathepsin l release and endorepellin proteolysis. J Biol Chem. 2008;283:27220-27229.
12. Gonzalez EM, Reed CC, Bix G, Fu J, Zhang Y, Gopalakrishnan B, Greenspan DS, Iozzo RV. Bmp-1/tolloid-like metalloproteases process endorepellin, the angiostatic c-terminal fragment of perlecan. J Biol Chem. 2005;280:7080-7087. (Pubitemid 40341264)
13. Laplante P, Raymond MA, Labelle A, Abe J, Iozzo RV, Hebert MJ. Perlecan proteolysis induces an alpha2beta1 integrin-and src family kinase-dependent anti-apoptotic pathway in fibroblasts in the absence of focal adhesion kinase activation. J Biol Chem. 2006;281:30383-30392. (Pubitemid 44582094)
14. Raymond MA, Desormeaux A, Laplante P, Vigneault N, Filep JG, Landry K, Pshezhetsky AV, Hebert MJ. Apoptosis of endothelial cells triggers a caspase-dependent anti-apoptotic paracrine loop active on vsmc. FASEB J. 2004;18:705-707.
15. Soulez M, Sirois I, Brassard N, Raymond MA, Nicodeme F, Noiseux N, Durocher Y, Pshezhetsky AV, Hebert MJ. Epidermal growth factor and perlecan fragments produced by apoptotic endothelial cells co-ordinately activate erk1/2-dependent antiapoptotic pathways in mesenchymal stem cells. Stem Cells. 2010;28:810-820.
16. Choy JC, Cruz RP, Kerjner A, Geisbrecht J, Sawchuk T, Fraser SA, Hudig D, Bleackley RC, Jirik FR, McManus BM, Granville DJ. Granzyme b induces endothelial cell apoptosis and contributes to the development of transplant vascular disease. Am J Transplant. 2005;5:494-499. (Pubitemid 40313340)
17. Dong C, Wilson JE, Winters GL, McManus BM. Human transplant coronary artery disease: pathological evidence for fas-mediated apoptotic cytotoxicity in allograft arteriopathy. Lab Invest. 1996;74:921-931.
18. Shimizu A, Yamada K, Sachs DH, Colvin RB. Mechanisms of chronic renal allograft rejection: I. Progressive allograft glomerulopathy in miniature swine. Lab Invest. 2002;82:673-686.
19. Bix G, Fu J, Gonzalez EM, Macro L, Barker A, Campbell S, Zutter MM, Santoro SA, Kim JK, Hook M, Reed CC, Iozzo RV. Endorepellin causes endothelial cell disassembly of actin cytoskeleton and focal adhesions through alpha2beta1 integrin. J Cell Biol. 2004;166:97-109. (Pubitemid 38931920)
20. Sis B, Mengel M, Haas M, Colvin RB, Halloran PF, Racusen LC, Solez K, Baldwin WM III, Bracamonte ER, Broecker V, Cosio F, Demetris AJ, Drachenberg C, Einecke G, Gloor J, Glotz D, Kraus E, Legendre C, Liapis H, Mannon RB, Nankivell BJ, Nickeleit V, Papadimitriou JC, Randhawa P, Regele H, Renaudin K, Rodriguez ER, Seron D, Seshan S, Suthanthiran M, Wasowska BA, Zachary A, Zeevi A. Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant. 2010;10:464-471.
21. Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, Krause M, Scharrer I, Aumann V, Mittler U, Solenthaler M, Lammle B. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med. 1998;339: 1578-1584. (Pubitemid 28536132)
22. Iozzo RV. Basement membrane proteoglycans: from cellar to ceiling. Nat Rev Mol Cell Biol. 2005;6:646-656. (Pubitemid 41081268)
23. Koulack J, McAlister VC, Giacomantonio CA, Bitter-Suermann H, Mac-Donald AS, Lee TD. Development of a mouse aortic transplant model of chronic rejection. Microsurgery. 1995;16:110-113.
24. Shimizu K, Sugiyama S, Aikawa M, Fukumoto Y, Rabkin E, Libby P, Mitchell RN. Host bone-marrow cells are a source of donor intimal smooth-muscle-like cells in murine aortic transplant arteriopathy. Nat Med. 2001;7:738-741. (Pubitemid 32588032)
25. Savani RC, Wang C, Yang B, Zhang S, Kinsella MG, Wight TN, Stern R, Nance DM, Turley EA. Migration of bovine aortic smooth muscle cells after wounding injury. The role of hyaluronan and rhamm. J Clin Invest. 1995;95:1158-1168.
26. Legare JF, Issekutz T, Lee TD, Hirsch G. Cd8+ t lymphocytes mediate destruction of the vascular media in a model of chronic rejection. Am J Pathol. 2000;157:859-865. (Pubitemid 32109378)
27. Yu PJ, Ferrari G, Pirelli L, Gulkarov I, Galloway AC, Mignatti P, Pintucci G. Vascular injury and modulation of mapks: a targeted approach to therapy of restenosis. Cell Signal. 2007;19:1359-1371. (Pubitemid 46818925)
28. Kawai M, Kitade H, Koshiba T, Waer M, Pirenne J. Intestinal ischemia reperfusion and lipopolysaccharide transform a tolerogenic signal into a sensitizing signal and trigger rejection. Transplantation. 2009;87: 1464-1467.
29. O'Riordan EOT, Mendelev N, Patschan D, Kemp R, Chander P, Hu R, Hao G, Gross S, Iozzo R, Delaney V, Goligorsky M. Urinary proteomic analysis of chronic allograft nephropathy. Proteomics Clin Appl. 2008;2: 1025-1035.
30. Chen XL, Chen ZS, Ding Z, Dong C, Guo H, Gong NQ. Antisense extracellular signal-regulated kinase-2 gene therapy inhibits plateletderived growth factor-induced proliferation, migration and transforming growth factor-beta(1) expression in vascular smooth muscle cells and attenuates transplant vasculopathy. Transpl Int. 2008;21:30-38. (Pubitemid 350198292)